csirt@kutim:~/threat-intel/cve/CVE-2024-47164

Katalog CVE

CVSS 6.5 · Medium EPSS 0,71%

Kerentanan Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal') pada gradio project gradio. Skor CVSS 3.1 6.5 (Medium) menurut NVD.

Deskripsi (NVD)

Gradio is an open-source Python package designed for quick prototyping. This vulnerability relates to the **bypass of directory traversal checks** within the `is_in_or_equal` function. This function, intended to check if a file resides within a given directory, can be bypassed with certain payloads that manipulate file paths using `..` (parent directory) sequences. Attackers could potentially access restricted files if they are able to exploit this flaw, although the difficulty is high. This primarily impacts users relying on Gradio’s blocklist or directory access validation, particularly when handling file uploads. Users are advised to upgrade to `gradio>=5.0` to address this issue. As a workaround, users can manually sanitize and normalize file paths in their Gradio deployment before passing them to the `is_in_or_equal` function. Ensuring that all file paths are properly resolved and absolute can help mitigate the bypass vulnerabilities caused by the improper handling of `..` sequences or malformed paths.

Rincian

Terbit di NVD
10 Oktober 2024
Terakhir diubah
17 Juni 2026
Status NVD
Analyzed
CVSS 3.1
6.5 (Medium), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-22: Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal')
EPSS (30 hari)
0,71% peluang dieksploitasi; lebih tinggi dari 52,1% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
gradio project gradio Semua versi sebelum 5.0.0

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.